

Estrogen Receptor - Pipeline Review, H2 2019

<https://marketpublishers.com/r/E6C44BDA7797EN.html>

Date: December 2019

Pages: 91

Price: US\$ 2,625.00 (Single User License)

ID: E6C44BDA7797EN

Abstracts

Estrogen Receptor - Pipeline Review, H2 2019

SUMMARY

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP.

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 27 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Women's Health and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Osteoporosis, Hormone Sensitive Breast Cancer, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hepatocellular Carcinoma, Male Hypogonadism, Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuromyelitis Optica (Devic's Syndrome), Non-Small Cell Lung Cancer,

Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).

The latest report Estrogen Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)

The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor

projects

The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics

Development

Amgen Inc

Arvinas Inc

AstraZeneca Plc

Atossa Genetics Inc

Avivia BV

Eagle Pharmaceuticals Inc

Endece LLC

EndoCeutics Inc

Evestra Inc

H3 Biomedicine Inc

Helixmith Co Ltd

Huons Co Ltd

Jina Pharmaceuticals Inc

Novartis AG

Shenogen Pharma Group Ltd

TTC Oncology LLC

Zenopharm LLC

Zentalis Pharmaceuticals LLC

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3
Group A Member 1 or NR3A1 or ESR1) - Drug Profiles

(bazedoxifene acetate + cholecalciferol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene + prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-471 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dehydrodiconiferyl alcohol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-372 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Endoxifen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ERX-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosfestrol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulvestrant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B5942 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

H-3B6545 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-07 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Loseasonique - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDC-1308 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-1153 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNG-8023 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-16234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTC-352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZB-716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZNc-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones

Featured News & Press Releases

Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate

Oct 24, 2019: Arvinas reports initial Phase I data for two cancer assets

Oct 17, 2019: Arvinas to present initial data from ARV-471 at the 2nd Targeted Protein Degradation Summit

Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology

Aug 27, 2019: Arvinas announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting PROTAC protein degrader

Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer

Jun 25, 2019: Arvinas receives authorization to proceed for ARV-471, a PROTAC Protein Degradator to treat patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer

May 16, 2019: Eisai Presents data on H3B-6545 at 55th ASCO Annual Meeting

Mar 27, 2019: Combo better for HR+ breast cancer patients

Dec 07, 2018: Arvinas presents preclinical data on protein degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)

Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant

Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy

Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCA) in ERα Wild-Type and Mutant Breast Cancer Models

Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston

Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Arvinas Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Atossa Genetics Inc, H2 2019
Pipeline by Avivia BV, H2 2019
Pipeline by Eagle Pharmaceuticals Inc, H2 2019
Pipeline by Endece LLC, H2 2019
Pipeline by EndoCeutics Inc, H2 2019
Pipeline by Evestra Inc, H2 2019
Pipeline by H3 Biomedicine Inc, H2 2019
Pipeline by Helixmith Co Ltd, H2 2019
Pipeline by Huons Co Ltd, H2 2019
Pipeline by Jina Pharmaceuticals Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Shenogen Pharma Group Ltd, H2 2019
Pipeline by TTC Oncology LLC, H2 2019
Pipeline by Zenopharm LLC, H2 2019
Pipeline by Zentalis Pharmaceuticals LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Amgen Inc
Arvinas Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Endece LLC
EndoCeutics Inc
Evestra Inc
H3 Biomedicine Inc
Helixmith Co Ltd
Huons Co Ltd
Jina Pharmaceuticals Inc
Novartis AG
Shenogen Pharma Group Ltd
TTC Oncology LLC
Zenopharm LLC
Zentalis Pharmaceuticals LLC

I would like to order

Product name: Estrogen Receptor - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/E6C44BDA7797EN.html>

Price: US\$ 2,625.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E6C44BDA7797EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970